Drisdol uses
Pro Research Analysisby 
Searched over 200M research papers for "drisdol uses"
Uses of Drisdol (Droperidol)
Introduction to Drisdol (Droperidol)
Drisdol, also known as droperidol, is a butyrophenone derivative that has been utilized in clinical settings for several decades. Initially approved by the U.S. Food and Drug Administration (FDA) in 1970, droperidol has been primarily used as an antiemetic and as an adjuvant during general anesthesia.
Management of Postoperative Nausea and Vomiting (PONV)
Efficacy in PONV Prevention
Droperidol is widely recognized for its effectiveness in preventing and treating postoperative nausea and vomiting (PONV). Clinical trials have demonstrated that a single dose of intravenous (IV) droperidol is as effective as ondansetron and dexamethasone in preventing PONV in surgical patients. This makes it a valuable option in the management of PONV, particularly in settings where cost-effectiveness is a consideration.
Opioid-Induced PONV
In addition to its general use in PONV, droperidol has shown significant efficacy in reducing opioid-induced PONV during patient-controlled analgesia (PCA) in adults. This is particularly beneficial as it also exhibits a morphine-sparing effect, potentially reducing the overall opioid requirement for pain management.
Safety and Tolerability
Adverse Effects
Droperidol is generally well tolerated, with an incidence of adverse effects comparable to that of placebo and serotonin 5-HT(3) receptor antagonists (setrons). This favorable safety profile supports its continued use in clinical practice, especially in patients at moderate to high risk of PONV.
Clinical Guidelines and Recommendations
Adult Patients
For adults, clinical guidelines recommend considering droperidol monotherapy for those at moderate risk of PONV. For patients at moderate or high risk, a combination of droperidol with a setron and/or dexamethasone is advised. This combination approach can enhance the antiemetic efficacy and provide better overall management of PONV.
Pediatric Patients
In pediatric patients, the recommendations for droperidol use vary by country. In some regions, it is recommended as a first-line treatment for children at moderate or high risk of PONV, while in others, it is considered a second-line option. This variability underscores the importance of adhering to local guidelines and individual patient considerations when using droperidol in pediatric populations.
Conclusion
Droperidol remains a valuable and cost-effective option for the management of postoperative nausea and vomiting, with a well-established safety profile. Its efficacy in both general and opioid-induced PONV, along with its recommended use in clinical guidelines, highlights its continued relevance in modern anesthetic practice.
Sources and full results
Most relevant research papers on this topic